{"id":31952,"date":"2024-04-16T11:47:08","date_gmt":"2024-04-16T09:47:08","guid":{"rendered":"https:\/\/www.mgc.es\/?p=31952"},"modified":"2024-04-22T09:48:23","modified_gmt":"2024-04-22T07:48:23","slug":"amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil","status":"publish","type":"post","link":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/","title":{"rendered":"El tractament per al c\u00e0ncer infantil d&#8217;Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"880\" height=\"587\" src=\"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_-880x587.jpg\" alt=\"\" class=\"wp-image-31953\" srcset=\"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_-880x587.jpg 880w, https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_-440x293.jpg 440w, https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_-768x512.jpg 768w, https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg 1000w\" sizes=\"auto, (max-width: 880px) 100vw, 880px\" \/><\/figure>\n\n\n\n<p>La Fundaci\u00f3 MGC est\u00e0 associada a Amira, la spin-off de <strong>Leitat<\/strong>, mitjan\u00e7ant un acord d&#8217;inversi\u00f3 signat l&#8217;any passat, en una aposta ferma i decidida per la innovaci\u00f3 i el desenvolupament de la investigaci\u00f3 biom\u00e8dica.<\/p>\n\n\n\n<p>Amira, biotecnol\u00f2gica innovadora dedicada a millorar la vida de pacients pedi\u00e0trics amb c\u00e0ncer i les seves fam\u00edlies, ha anunciat amb orgull que <strong>la US Food and Drug Administration (FDA) ha atorgat la Designaci\u00f3 de Medicament Orfe al seu compost AMI463 per al tractament del sarcoma de teixits tous.<\/strong> Aquesta fita crucial subratlla el comprom\u00eds d&#8217;abordar les necessitats no satisfetes en oncologia pedi\u00e0trica.<\/p>\n\n\n\n<p>El sarcoma de teixits tous, un grup rar i divers de tumors derivats de teixits connectius mesenquimals embrionaris, sovint comporta un mal pron\u00f2stic, amb limitades opcions de tractament m\u00e9s enll\u00e0 de la quimioter\u00e0pia. <strong>Amira est\u00e0 a l&#8217;avantguarda del desenvolupament d&#8217;AMI463, especialment per al rabdomiosarcoma, el sarcoma de teixits tous m\u00e9s com\u00fa en nens.<\/strong><\/p>\n\n\n\n<p>El rabdomiosarcoma, amb una incid\u00e8ncia anual d&#8217;uns 500 casos nous als EUA i uns 400 en menors de 18 anys a Europa, \u00e9s un c\u00e0ncer relacionat amb els m\u00fasculs caracteritzat per una activaci\u00f3 de la via de senyalitzaci\u00f3 Hedgehog, que afecta principalment els teixits musculars i els \u00f2rgans buits.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Tractaments prometedors per a malalties rares<\/strong><\/h2>\n\n\n\n<p>La Designaci\u00f3 de Medicament Orfe <strong>s&#8217;atorga a tractaments prometedors per a malalties rares, oferint beneficis com a assist\u00e8ncia en protocols i exclusivitat de mercat,<\/strong> recolzant encara m\u00e9s els seus esfor\u00e7os per portar AMI463 als pacients que ho necessiten.<\/p>\n\n\n\n<p>A m\u00e9s de l&#8217;actual designaci\u00f3 com a medicament orfe per la FDA, el compost AMI463 ha estat recentment reconegut, tamb\u00e9 per la FDA, amb la Rare Pediatric Disease Designation, aix\u00ed com tamb\u00e9 havia rebut pr\u00e8viament la Designaci\u00f3 de Medicament Orfe per part de l&#8217;Ag\u00e8ncia Europea del Medicament (EMA), cosa que suposar\u00e0 un suport al desenvolupament i una protecci\u00f3 en la seva comercialitzaci\u00f3 tamb\u00e9 a Europa.<\/p>\n\n\n\n<p>Aquests reconeixements per part de les ag\u00e8ncies reguladores reforcen el comprom\u00eds d&#8217;expandir l&#8217;abast dels seus tractaments innovadors i abordar el desafiament global del c\u00e0ncer pedi\u00e0tric.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Fundaci\u00f3 MGC est\u00e0 associada a Amira, la spin-off de Leitat, mitjan\u00e7ant un acord d&#8217;inversi\u00f3 signat l&#8217;any passat, en una aposta ferma i decidida per la innovaci\u00f3 i el desenvolupament de la investigaci\u00f3 biom\u00e8dica. Amira, biotecnol\u00f2gica innovadora dedicada a millorar la vida de pacients pedi\u00e0trics amb c\u00e0ncer i les seves fam\u00edlies, ha anunciat amb orgull [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":31953,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,15],"tags":[],"class_list":["post-31952","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualitat","category-salut"],"featured_image_src":"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg","author_info":{"display_name":"Revista Inter\u00e8s Mutu","author_link":"https:\/\/www.mgc.es\/ca\/blog\/author\/interesmutu\/"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>El tractament per al c\u00e0ncer infantil d&#039;Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA - MGC M\u00fatua<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"El tractament per al c\u00e0ncer infantil d&#039;Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA - MGC M\u00fatua\" \/>\n<meta property=\"og:description\" content=\"La Fundaci\u00f3 MGC est\u00e0 associada a Amira, la spin-off de Leitat, mitjan\u00e7ant un acord d&#8217;inversi\u00f3 signat l&#8217;any passat, en una aposta ferma i decidida per la innovaci\u00f3 i el desenvolupament de la investigaci\u00f3 biom\u00e8dica. Amira, biotecnol\u00f2gica innovadora dedicada a millorar la vida de pacients pedi\u00e0trics amb c\u00e0ncer i les seves fam\u00edlies, ha anunciat amb orgull [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/\" \/>\n<meta property=\"og:site_name\" content=\"MGC M\u00fatua\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/mgcmutua\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-16T09:47:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-22T07:48:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Revista Inter\u00e8s Mutu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@mgcmutua\" \/>\n<meta name=\"twitter:site\" content=\"@mgcmutua\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Revista Inter\u00e8s Mutu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El tractament per al c\u00e0ncer infantil d'Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA - MGC M\u00fatua","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/","og_locale":"ca_ES","og_type":"article","og_title":"El tractament per al c\u00e0ncer infantil d'Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA - MGC M\u00fatua","og_description":"La Fundaci\u00f3 MGC est\u00e0 associada a Amira, la spin-off de Leitat, mitjan\u00e7ant un acord d&#8217;inversi\u00f3 signat l&#8217;any passat, en una aposta ferma i decidida per la innovaci\u00f3 i el desenvolupament de la investigaci\u00f3 biom\u00e8dica. Amira, biotecnol\u00f2gica innovadora dedicada a millorar la vida de pacients pedi\u00e0trics amb c\u00e0ncer i les seves fam\u00edlies, ha anunciat amb orgull [&hellip;]","og_url":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/","og_site_name":"MGC M\u00fatua","article_publisher":"https:\/\/www.facebook.com\/mgcmutua","article_published_time":"2024-04-16T09:47:08+00:00","article_modified_time":"2024-04-22T07:48:23+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg","type":"image\/jpeg"}],"author":"Revista Inter\u00e8s Mutu","twitter_card":"summary_large_image","twitter_creator":"@mgcmutua","twitter_site":"@mgcmutua","twitter_misc":{"Escrit per":"Revista Inter\u00e8s Mutu","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","BlogPosting"],"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/#article","isPartOf":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/"},"author":{"name":"Revista Inter\u00e8s Mutu","@id":"https:\/\/www.mgc.es\/#\/schema\/person\/010c961d9c9acf38f11187a02b646c16"},"headline":"El tractament per al c\u00e0ncer infantil d&#8217;Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA","datePublished":"2024-04-16T09:47:08+00:00","dateModified":"2024-04-22T07:48:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/"},"wordCount":375,"publisher":{"@id":"https:\/\/www.mgc.es\/#organization"},"image":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg","articleSection":["Actualitat M\u00fatua","Salut i medicina"],"inLanguage":"ca"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/","url":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/","name":"El tractament per al c\u00e0ncer infantil d'Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA - MGC M\u00fatua","isPartOf":{"@id":"https:\/\/www.mgc.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/#primaryimage"},"image":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg","datePublished":"2024-04-16T09:47:08+00:00","dateModified":"2024-04-22T07:48:23+00:00","breadcrumb":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/#primaryimage","url":"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg","contentUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2024\/04\/cancer-infantil_amira_.jpg","width":1000,"height":667},{"@type":"BreadcrumbList","@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-therapeutics-rep-laprovacio-de-la-fda-als-estats-units-pel-seu-tractament-del-cancer-infantil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mgc.es\/ca\/"},{"@type":"ListItem","position":2,"name":"El tractament per al c\u00e0ncer infantil d&#8217;Amira therapeutics rep la designaci\u00f3 com a medicament orfe per part de la FDA"}]},{"@type":"WebSite","@id":"https:\/\/www.mgc.es\/#website","url":"https:\/\/www.mgc.es\/","name":"MGC M\u00fatua","description":"MGC M\u00fatua \u00e9s una entitat asseguradora sense \u00e0nim de lucre constitu\u00efda al 1982 i especialitzada en assegurances de salut i assist\u00e8ncia.","publisher":{"@id":"https:\/\/www.mgc.es\/#organization"},"alternateName":"MGC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mgc.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.mgc.es\/#organization","name":"MGC Mutua","alternateName":"MGC","url":"https:\/\/www.mgc.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.mgc.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.mgc.es\/wp-content\/uploads\/2020\/03\/mgcmutua_h2_2t_reduccions.png","contentUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2020\/03\/mgcmutua_h2_2t_reduccions.png","width":303,"height":165,"caption":"MGC Mutua"},"image":{"@id":"https:\/\/www.mgc.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/mgcmutua","https:\/\/x.com\/mgcmutua","https:\/\/www.youtube.com\/c\/MGCMutua"]},{"@type":"Person","@id":"https:\/\/www.mgc.es\/#\/schema\/person\/010c961d9c9acf38f11187a02b646c16","name":"Revista Inter\u00e8s Mutu","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/52302d684339b9d7bf5691e2ad00835d62ce3b4a435f21ca9f21fbe39c63cb1b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/52302d684339b9d7bf5691e2ad00835d62ce3b4a435f21ca9f21fbe39c63cb1b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/52302d684339b9d7bf5691e2ad00835d62ce3b4a435f21ca9f21fbe39c63cb1b?s=96&d=mm&r=g","caption":"Revista Inter\u00e8s Mutu"}}]}},"_links":{"self":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts\/31952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/comments?post=31952"}],"version-history":[{"count":4,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts\/31952\/revisions"}],"predecessor-version":[{"id":31972,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts\/31952\/revisions\/31972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/media\/31953"}],"wp:attachment":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/media?parent=31952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/categories?post=31952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/tags?post=31952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}